Nuformix plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Alastair Riddell, was filed 10 Jan 2022.
Nuformix plc: what insiders have been doing
Every trade that managers of Nuformix plc disclose to RNS (LSE) is tracked on this page. The past year has been quiet: not a single insider filing for Nuformix plc. The previous disclosure was published on 31 January 2022.
The full history, which starts in 2018, counts 3 purchases against no sales.
Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
- 3,000,000 sharesOff-market transactionISIN GB00BYW79Y38FCA-NSM:4257198-0
- 3,000,000 sharesOff-market transactionISIN GB00BYW79Y38FCA-NSM:4257198-1
- 3,000,000 sharesOff-market transactionISIN GB00BYW79Y38FCA-NSM:4257198-2
- 400,000 shares@ £0.0117London Stock Exchange, Main MarketISIN GB00BYW79Y38FCA-NSM:4235104Canonical exit: 10 Apr 2022 (T+90)
- 350,000 shares@ £0.0001London Stock Exchange, Main MarketISIN GB00BYW79Y38FCA-NSM:4112744Canonical exit: 15 Dec 2021 (T+90)
- 35,364 shares@ £0.026100.0% of flowStandard List, London Stock ExchangeISIN GB00BYW79Y38FCA-NSM:LSE20180928100955_13808749_20200330111446001_1038Canonical exit: 27 Dec 2018 (T+90)
6 of 6 declarations
About Nuformix plc
Nuformix plc is a biopharmaceutical company focused on developing treatments for serious diseases using advanced formulation technologies. It is listed on the London Stock Exchange.
